Last €46.72 EUR
Change Today +0.091 / 0.20%
Volume 3.2K
MDT On Other Exchanges
Symbol
Exchange
New York
Mexico
Frankfurt
As of 10:15 AM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

medtronic inc (MDT) Snapshot

Open
€46.56
Previous Close
€46.62
Day High
€46.98
Day Low
€46.36
52 Week High
06/16/14 - €50.76
52 Week Low
08/28/13 - €38.20
Market Cap
46.5B
Average Volume 10 Days
8.5K
EPS TTM
--
Shares Outstanding
996.2M
EX-Date
07/1/14
P/E TM
--
Dividend
€1.21
Dividend Yield
1.79%
Current Stock Chart for MEDTRONIC INC (MDT)

medtronic inc (MDT) Details

Medtronic, Inc. manufactures and sells device-based medical therapies worldwide. It operates through three segments: Cardiac and Vascular Group, Restorative Therapies Group, and Diabetes Group. The Cardiac and Vascular Group’s products include pacemakers; insertable cardiac monitors; implantable defibrillators; leads and delivery systems; ablation products; electrophysiology catheters; products for the treatment of atrial fibrillation; information systems for the management of patients with cardiac rhythm disease management devices; products to reduce surgical site infections; coronary and peripheral stents and related delivery systems; therapies for uncontrolled hypertension; endovascular stent graft systems; heart valve replacement technologies; cardiac tissue ablation systems; and open heart and coronary bypass grafting surgical products. The Restorative Therapies Group offers products for various areas of the spine; bone graft substitutes; biologic products; trauma, implantable neurostimulation therapies, and drug delivery systems for the treatment of chronic pain, movement disorders, obsessive-compulsive disorder, overactive bladder, urinary retention, fecal incontinence, and gastroparesis; products to treat conditions of the ear, nose, and throat; and systems that incorporate advanced energy surgical instruments. It also manufactures and sells image-guided surgery and intra-operative imaging systems. The Diabetes Group’s products include insulin pumps; continuous glucose monitoring systems; insulin pump consumables; and Web-based therapy management software solutions. The company serves hospitals, physicians, clinicians, and patients in approximately 140 countries. Medtronic, Inc. was founded in 1949 and is headquartered in Minneapolis, Minnesota.

49,247 Employees
Last Reported Date: 06/20/14
Founded in 1949

medtronic inc (MDT) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $1.5M
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $774.9K
Executive Vice President and Group President ...
Total Annual Compensation: $724.9K
Executive Vice President and Group President ...
Total Annual Compensation: $675.1K
Chief Human Resources Officer and Senior Vice...
Total Annual Compensation: $781.7K
Compensation as of Fiscal Year 2014.

medtronic inc (MDT) Key Developments

Medtronic Discloses Minnesota Job Cuts

Medtronic Inc. disclosed 40 Minnesota job cuts but isn't providing many more details. The eliminated positions are in Fridley, the headquarters for its corporate functions and neuromodulation business, and in Mounds View, where its cardiac rhythm disease management and structural heart divisions are based.

Medtronic, Inc. Announces Results of the Global OpT2mise Trial

Medtronic, Inc. announced the results of the global OpT2mise trial, which included eight participating centers in Canada. The results showed that MiniMed insulin pumps safely achieve better glucose control for people with insulin-requiring type 2 diabetes than multiple daily injections. While the benefits of continuous subcutaneous insulin infusion with an insulin pump for people with type 1 diabetes are well proven, this is the largest global study to evaluate the comparative efficacy of CSII with an insulin pump versus multiple daily insulin injections in people with type 2 diabetes with poor glycemic control. In the OpT2mise trial, those using insulin pumps achieved a mean A1C (average blood glucose) reduction of 1.1% compared to only a 0.4% reduction by those using multiple daily injections. This improvement in glucose control was achieved without any episodes of severe hypoglycemia. In addition, those in the insulin pump group lowered the total daily dose of insulin by more than 20%. There was no difference in weight gain between the two groups. Reducing A1C is critical for people with diabetes because even small percent drops aid significantly in preventing complications, such as eye disease, kidney disease, nerve damage and heart attacks. Approximately 20 million people around the world with type 2 diabetes require insulin replacement therapy and adherence to insulin therapy can be a challenge, with 57% of patients on MDI therapy admitting to omitting insulin injections. The global, randomized, controlled study was sponsored by Medtronic and conducted with participation from 331 patients, ranging in age from 30 to 75 years. Eight centres across Canada participated in the study. Specific results include: Those using insulin pumps demonstrated a mean reduction of A1C levels by 1.1%, vs. only 0.4% for participants using multiple daily injections (P < 0.001). Those in the CSII arm experienced the A1C reduction without any episodes of severe hypoglycemia (low blood sugar, which can cause confusion, disorientation, loss of consciousness, and in the worst cases coma and even death) or ketoacidosis (a potentially life-threatening condition caused by hyperglycemia or high blood sugar). The total daily insulin dose was 20.4% lower with CSII than with injection therapy (P < 0.001) with no significant difference in body weight change between the two groups. The percentage of participants in the CSII group achieving an A1C < 8% was twice that of the multiple daily injections group (55% vs. 28%).

Medtronic, Inc. Announces Encouraging Preliminary Data from a Trial with Micra Transcatheter Pacing System, or TPS

Medtronic, Inc. has announced encouraging preliminary data from a trial with Micra Transcatheter Pacing System, or TPS. At 1 month and 3 months, results showed the Micra TPS was successfully implanted in all patients, whose ages ranged from 74 to 83 years, and there were no major complications post-implant. The device performed as expected, and electrical values were within normal ranges. The Micra TPS is an investigational device worldwide and not approved in the US, and its safety and efficacy is currently being evaluated in the Medtronic Micra Transcatheter Pacing System (TPS) Global Clinical Trial. The Trial is a single-arm, multi-center study that will enroll up to 780 patients at approximately 50 centers. The miniature device does not require a surgical incision or the creation of a "pocket" under the skin, which eliminates any visible sign of the device and a potential source of device-related complications. At one-tenth the size of a conventional pacemaker, and comparable in size to a large vitamin, the Micra TPS is delivered directly into the heart through a catheter inserted in the femoral vein. Once positioned, the pacemaker is securely attached to the heart wall and can be repositioned or retrieved if needed. The Micra TPS does not require the use of wires, known as ‘leads’ to connect to the heart, and is attached via small tines which secure the Micra TPS to deliver electrical impulses that pace the heart.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MDT:GR €46.72 EUR +0.091

MDT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $41.30 USD +0.06
Allergan Inc/United States $166.43 USD +0.83
Astellas Pharma Inc ¥1,349 JPY +10.00
Baxter International Inc $76.59 USD -0.16
Covidien PLC $91.37 USD +0.37
View Industry Companies
 

Industry Analysis

MDT

Industry Average

Valuation MDT Industry Range
Price/Earnings 21.1x
Price/Sales 3.8x
Price/Book 3.3x
Price/Cash Flow 18.6x
TEV/Sales 2.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDTRONIC INC, please visit www.medtronic.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.